Abzena attended the Next Generation Conjugates Summit from 21st-23rd February 2023!
The 2nd Next-Generation Conjugate Summit was your only platform dedicated to showcasing out-of-the-box technologies and approaches to design conjugates with novel modes of action.
Below see Thomas Smith, from Novartis Institutes for BioMedical Research (NIBR) talk about ‘Extracellular Targeted Protein Degradation: An Emerging Therapeutic Modality’.
Thomas Smith is an Associate Director in the department of Chemical Biology; Therapeutics at the Novartis Institutes for Biomedical Research in Cambridge, MA, USA. Dr. Smith works with project teams from multiple disease areas on new therapeutic modalities, drug prototypes, and enabling early-stage drug discovery efforts against disease-relevant targets of interest. Prior to Novartis, he was a research scientist in the Department of Cardiovascular and Metabolic Diseases at Genetics Institute / Wyeth Research in Cambridge, MA, USA focusing on platelet biology and therapies for cardiovascular diseases. He completed a MA and PhD in the department of Biological Sciences at the University at Buffalo, NY, USA, whilst his post-doctoral studies were at the University of Cincinnati College of Medicine, OH, USA studying anti-platelet agents from the saliva of blood-feeding arthropods.
View the slides here and contact us to discuss your next-generation development.
